International Isotope Society. Abstracts of the Xth I.I.S. (UK Group) Symposium. Current themes in Isotopic chemistry.

The tenth annual symposium of the International Isotope Society's United Kingdom Group took place at the Alderley Park site of AstraZeneca plc. The symposium was attended by over 80 delegates from academia, the pharmaceutical and agrochemical industries, life science and fine chemical companies. Delegates were welcomed to the site by Dr Peter Warner of the Medicinal Chemistry Department. The scientific programme consisted of presentations on isotopic chemistry and applications of labelled compounds, or of chemistry with significant implications for isotopic synthesis. Both short-lived and long-lived isotopes were represented, as were stable isotopes. The programme was split into a morning and afternoon session chaired by Dr John Harding (AstraZeneca, who also organised the excellent domestic programme) and Dr Karl Cable (Glaxo Wellcome). The meeting ended with concluding remarks from Dr Ken Lawrie (SmithKline Beecham), chairman of the UK Group. This years symposium had a larger attendance from other European countries, an excellent level of sponsorship was achieved, and the symposium proved self-financing. The next UK group symposium is planned for early October 2001. Meeting Programme Paul Pringle [University of Bristol, UK] To what extent can Homogeneous Catalysts be Designed? Henrick Olsen [Novo Nordisk, Denmark] Mapping of Pharmaceutical Degradation Products in the Solid Dosage Form using Radiotracers. Marie-Claire Lasne [University of Caen, France] Synthesis of New Ligands of Cholinergic Receptors. Strategies for their Radiolabelling with Positron Emitters, Carbon-11 or Fluorine-18. Christopher Rayner [University of Leeds, UK] Catalysis in Supercritical Carbon Dioxide - What advantages does it have to Offer? Gunnar Antoni, [University of Uppsala, Sweden] Position Specific Labelling of Biomedically Interesting Compounds using Short-Lived Radionuclides. Hugh Wiltshire [Hoffmann-La Roche, UK] The Use of Stable-Labelled Isotopes in Bioequivalence Studies with the HIV-Protease inhibitor Saquinavir. Alison Hill [Kings College, UK] Elucidation of Soraphen A Biosynthesis using2H, 13C and18O-Labelled Precursors. Nick Shipley [Glaxo Wellcome, UK] Preparation of P450 Substrates for use in Drug-drug Interactions Andrew Mather [AstraZeneca, UK] Aspects of Isotopic Labelling by Parallel Chemistry. Helen Booth [Astra Zeneca, UK] Synthesis of14C-labelled forms of a series of Human Leukocyte Elastase Inhibitors.

[1]  L. Kingston,et al.  Parallel chemistry investigations of ortho-directed hydrogen isotope exchange between substituted aromatics and isotopic water: novel catalysis by cyclooctadienyliridium(I)pentan-1,3-dionates , 2000 .

[2]  A. Orpen,et al.  Rationally designed improvement of the bis(phospholano)ethane ligand for asymmetric hydrogenation leads to a reappraisal of the factors governing the enantioselectivity of Duphos catalysts , 2000 .

[3]  B. Långström,et al.  Biologically Active 11C-Labeled Amides Using Palladium-Mediated Reactions with Aryl Halides and [11C]Carbon Monoxide , 1999 .

[4]  R. Oakes,et al.  Use of fluorinated palladium sources for efficient Pd-catalysed coupling reactions in supercritical carbon dioxide , 1999 .

[5]  A. Buck,et al.  Synthesis and in Vivo studies of [C-11]N-methylepibatidine: comparison of the stereoisomers. , 1999, Nuclear medicine and biology.

[6]  R. Oakes,et al.  Use of scandium tris(trifluoromethanesulfonate) as a Lewis acid catalyst in supercritical carbon dioxide: efficient Diels–Alder reactions and pressure dependent enhancement of endo:exo stereoselectivity , 1999 .

[7]  R. Oakes,et al.  Sulfur oxidation in supercritical carbon dioxide: dramatic pressure dependant enhancement of diastereoselectivity for sulfoxidation of cysteine derivatives , 1999 .

[8]  J S Fowler,et al.  Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. , 1999, Nuclear medicine and biology.

[9]  H. Schönenberger,et al.  The synthesis of labelled forms of saquinavir , 1998 .

[10]  E. London,et al.  Synthesis and evaluation of N-[11C]methylated analogues of epibatidine as tracers for positron emission tomographic studies of nicotinic acetylcholine receptors. , 1998, Journal of medicinal chemistry.

[11]  Yasuyoshi Watanabe,et al.  In Vitro Evaluation of 11C‐Labeled (S)‐Nicotine, (S)‐3‐Methyl‐5‐(1‐Methyl‐2‐Pyrrolidinyl)isoxazole, and (R,S)‐1‐Methyl‐2‐(3‐Pyridyl)azetidine as Nicotinic Receptor Ligands for Positron Emission Tomography Studies , 1998, Journal of neurochemistry.

[12]  E. London,et al.  Pharmacological evaluation of [11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. , 1998, Life sciences.

[13]  R. Dannals,et al.  5-[I-125/123]lodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. , 1998, Life sciences.

[14]  B. Långstrom,et al.  Synthesis of D-[1-C-11]mannitol and its enzymatic oxidation to D-[1/6-C-11]fructose , 1998 .

[15]  A. Hill,et al.  Investigation of glycerol incorporation into soraphen A , 1998 .

[16]  E. London,et al.  [125/123I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors , 1997, Synapse.

[17]  M. Bergström,et al.  Synthesis of L-2,4-diamino[4-11C]butyric acid and its use in some in vitro and in vivo tumour models. , 1997, Nuclear medicine and biology.

[18]  B. Långström,et al.  Synthesis of O-[11C]Acetyl CoA, O-[11C]Acetyl-L-carnitine, and L-[11C]carnitine labelled in specific positions, applied in PET studies on rhesus monkey. , 1997, Nuclear medicine and biology.

[19]  A. Wolf,et al.  Working Against Time: Rapid Radiotracer Synthesis and Imaging the Human Brain , 1997 .

[20]  Y. Yonekura,et al.  Synthesis and characterization of radioiodinated (S)-5-iodonicotine: a new ligand for potential imaging of brain nicotinic cholinergic receptors by single photon emission computed tomography. , 1997, Chemical & pharmaceutical bulletin.

[21]  T Machii,et al.  High uptake of [2-11C]acetyl-L-carnitine into the brain: a PET study. , 1997, Biochemical and biophysical research communications.

[22]  C. Crouzel,et al.  An attempt to visualize baboon brain nicotinic receptors with N-[11C]ABT‐418 and N-[11C]methyl‐cytisine , 1997, Nuclear medicine communications.

[23]  C. Foged,et al.  Mapping of Pharmaceutical Degradants of Gabitril Using Radiotracers , 1996 .

[24]  D. Irving,et al.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology , 1995, Neuroscience.

[25]  M. Maziére Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography. , 1995, Pharmacology & therapeutics.

[26]  S. Arneric,et al.  Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain. , 1994, European journal of pharmacology.

[27]  R. Freedman,et al.  Characterization of [3H]cytisine binding to human brain membrane preparations , 1993, Brain Research.

[28]  K. Kellar,et al.  [3H]cytisine binding to nicotinic cholinergic receptors in brain. , 1991, Molecular pharmacology.

[29]  Yasuyoshi Watanabe,et al.  Syntheses of β-11C-labelled L-tryptophan and 5-hydroxy-L-tryptophan using a multi-enzymatic reaction route , 1989 .

[30]  R. Hook,et al.  The comparative binding characteristics of nicotinic ligands and their pharmacology , 1988, Pharmacology Biochemistry and Behavior.